Cohance Lifesciences Q3FY26 Investor Presentation Highlights Transition Phase
Cohance Lifesciences reports a transition phase for FY26 with revised revenue guidance to a double-digit decline. The company achieved EcoVadis Gold for sustainability. 9MFY26 revenue was ₹16.5 billion, with free cash flow of ₹1.75 billion. Investments continue in R&D and capacity expansion, with an expected return to growth in FY27.
The revised revenue guidance and current financial performance indicate a near-term impact on revenue and profitability. However, the company's strategic focus on long-term growth drivers, investments in new technologies, and sustainability initiatives suggest a medium-term positive outlook, making the impact medium.
The company is in a transition phase with revised revenue guidance indicating a decline for FY26, which is a negative factor. However, achievements like EcoVadis Gold, ongoing investments in growth areas, and an expected return to growth in FY27 provide a balanced outlook, leading to a neutral sentiment.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has released its investor presentation for the quarter and nine months ended December 31, 2025. The company is undergoing a transition and bottoming phase, impacted by portfolio mix changes, customer-led inventory normalization, and timing shifts in select programs. The FY26 revenue guidance has been revised to an early-to-mid double-digit decline, a shift from the earlier flat outlook, due to incremental timing effects.
The company has completed leadership appointments and upgraded functional depth across Business Development, Quality, Regulatory, R&D, and Operations. Technology-led platforms are reported to remain intact and differentiated, with current softness attributed to timing and product-mix rather than structural issues. Cohance has been awarded EcoVadis Gold, highlighting its governance, compliance, and sustainability credentials.
Pharma CDMO segment experienced a decline, partly due to de-stocking of two large commercial products and earlier-than-expected lifecycle moderation in mature products. RFQ intensity has doubled year-to-date, with significant innovator and biotech audits conducted. The commercial pipeline includes 9 Phase III assets, with 4 expected to move to commercial supply in the coming fiscal.
ADC and Oligos segments show a stable long-term outlook. An ADC expansion is underway in the US, and a new building-block facility for Oligonucleotides is nearing operationalization. Subsidiaries/NJ Bio's trajectory is expected to remain muted into FY27 due to customer trial delays and biotech funding cycles.
Specialty Chemicals (Spec/Ag Chem) progress is in line with the plan, though FY26 is impacted by regulatory timing and longer qualification cycles. API+ segment performance is shaped by product-level normalization, including shipment timing and pricing resets. The Nacham FDF plant has resumed operations in a phased manner for non-US markets post-FDA Warning Letter remediation.
Financially, for 9MFY26, revenue declined by 6.7% YoY to ₹16.5 billion, with Adjusted EBITDA at ₹3.5 billion and Adjusted PAT at ₹1.5 billion. Free cash flow generated was ₹1.75 billion, and the company maintained a healthy liquidity position with ₹4.32 billion cash on books. Capex deployed was ₹1.61 billion, primarily for facility expansions and upgrades.
For Q3FY26, revenue saw a significant YoY decline of 19.5% to ₹5.45 billion, with Adjusted EBITDA at ₹847 million and Adjusted PAT at ₹211 million. The company is investing in team building and enhancing capabilities across its platform, expecting a return to revenue growth in FY27.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.